149 related articles for article (PubMed ID: 38838423)
1. Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis.
Vaheb S; Afshin S; Ghoshouni H; Ghaffary EM; Farzan M; Shaygannejad V; Thapa S; Zabeti A; Mirmosayyeb O
Mult Scler Relat Disord; 2024 Jul; 87():105681. PubMed ID: 38838423
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
3. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
Cohen JA; Imrey PB; Planchon SM; Bermel RA; Fisher E; Fox RJ; Bar-Or A; Sharp SL; Skaramagas TT; Jagodnik P; Karafa M; Morrison S; Reese Koc J; Gerson SL; Lazarus HM
Mult Scler; 2018 Apr; 24(4):501-511. PubMed ID: 28381130
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.
Petrou P; Kassis I; Levin N; Paul F; Backner Y; Benoliel T; Oertel FC; Scheel M; Hallimi M; Yaghmour N; Hur TB; Ginzberg A; Levy Y; Abramsky O; Karussis D
Brain; 2020 Dec; 143(12):3574-3588. PubMed ID: 33253391
[TBL] [Abstract][Full Text] [Related]
5. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
[TBL] [Abstract][Full Text] [Related]
6. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.
Llufriu S; Sepúlveda M; Blanco Y; Marín P; Moreno B; Berenguer J; Gabilondo I; Martínez-Heras E; Sola-Valls N; Arnaiz JA; Andreu EJ; Fernández B; Bullich S; Sánchez-Dalmau B; Graus F; Villoslada P; Saiz A
PLoS One; 2014; 9(12):e113936. PubMed ID: 25436769
[TBL] [Abstract][Full Text] [Related]
7. Disease modifying therapy management of multiple sclerosis after stem cell therapies: A retrospective case series.
Manzano GS; Holroyd KB; Kaplan T; Bhattacharyya S; Chitnis T; Hotan G; Zurawski J; Galetta KM; Mateen FJ
Mult Scler Relat Disord; 2022 Jul; 63():103861. PubMed ID: 35576727
[TBL] [Abstract][Full Text] [Related]
8. Muscle Quality of Knee Extensors Based on Several Types of Force in Multiple Sclerosis Patients with Varying Degrees of Disability.
Portilla-Cueto K; Medina-Pérez C; Romero-Pérez EM; Núñez-Othón G; Horta-Gim MA; de Paz JA
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208639
[No Abstract] [Full Text] [Related]
9. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS;
Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636
[TBL] [Abstract][Full Text] [Related]
10. Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: A systematic review.
Oliveira AG; Gonçalves M; Ferreira H; M Neves N
Mult Scler Relat Disord; 2020 Feb; 38():101860. PubMed ID: 31765999
[TBL] [Abstract][Full Text] [Related]
11. Serum amino acid profiling in differentiating clinical outcomes of multiple sclerosis.
Rzepiński Ł; Kośliński P; Kowalewski M; Koba M; Maciejek Z
Neurol Neurochir Pol; 2023; 57(5):414-422. PubMed ID: 37526173
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
13. Sex impacts treatment decisions in multiple sclerosis.
Hegen H; Berek K; Deisenhammer F; Berger T; Enzinger C; Guger M; Kraus J; Walde J; Di Pauli F
J Neurol; 2024 Jun; 271(6):3256-3267. PubMed ID: 38441611
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial.
Harris VK; Stark J; Williams A; Roche M; Malin M; Kumar A; Carlson AL; Kizilbash C; Wollowitz J; Andy C; Gerber LM; Sadiq SA
Stem Cell Res Ther; 2024 May; 15(1):151. PubMed ID: 38783390
[TBL] [Abstract][Full Text] [Related]
15. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.
Harris VK; Vyshkina T; Sadiq SA
Cytotherapy; 2016 Dec; 18(12):1476-1482. PubMed ID: 27727015
[TBL] [Abstract][Full Text] [Related]
16. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
17. Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis.
Gernert JA; Böhm L; Starck M; Buchka S; Kümpfel T; Kleiter I; Havla J
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629053
[TBL] [Abstract][Full Text] [Related]
18. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stem cell transplantation in multiple sclerosis.
Cohen JA
J Neurol Sci; 2013 Oct; 333(1-2):43-9. PubMed ID: 23294498
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
